Biogen Goodwill

Biogen (BIIB) currently reports a goodwill of $6.5B as of March 2026. That compares with $6.5B in the prior-year period — up 0.2% year over year. Use the charts on this page to explore Biogen's goodwill history and peer comparisons.

Biogen's goodwill increased from $6.5B to $6.5B — a 0.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biogen reported $6.5B in goodwill as of March 2026. That compares with $6.5B in the prior-year period — up 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $6.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biogen, and consider following BIIB for alerts when major investors trade the stock.

Biogen is classified in the Healthcare sector. On goodwill, it currently shows $6.5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIIB with unrelated industries.